Robert Bell

Robert Bell has extensive experience in research and development. Robert began their career in 2004 as an Associate Scientist at Socratech Research Labs LLC. In 2010, they moved to The University of Rochester Medical Center, Center for Neurodegenerative and Vascular Brain Disorder, where they worked as a Research Assistant Professor. In 2011, they transitioned to the University of Rochester, Aab Cardiovascular Research Institute & Department of Medicine, where they held a Cardiovascular Postdoctoral Research Fellowship. In 2012, they joined Pfizer as an Associate Research Fellow in the Gene Therapy, Rare Disease Research Unit, and later became a Principal to Senior Principal Scientist in the Neuroscience Research Unit. In 2021, they moved to Ascidian Therapeutics as SVP, Head of Research.

Robert Bell obtained a PhD in Pathology from the University of Rochester School of Medicine and Dentistry between 2006 and 2010. Robert also obtained a BS in Psychology and Biology from St. Bonaventure University between 2000 and 2004. In 2002, they attended Oxford University to study the Theirtory of Natural Sciences. Robert also attended Aquinas Institute, New York from 1996 to 2000 and obtained a New York State Regents certification.